Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.
about
Fecal transplantation for recurrent or refractory Clostridium difficile diarrheaBench-to-bedside review: Clostridium difficile colitisDetection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assayRecent advances in the understanding of antibiotic resistance in Clostridium difficile infectionDisruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic ResistanceThe Role of Rho GTPases in Toxicity of Clostridium difficile ToxinsClostridium difficile Infection in Children: Current State and Unanswered QuestionsRisk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic reviewOveruse of antimicrobial prophylaxis in community practice urology.Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionDiversity and Evolution in the Genome of Clostridium difficileFecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and BeyondPredictors of Clostridium difficile colitis infections in hospitalsMetabolism of bile salts in mice influences spore germination in Clostridium difficileThe changing epidemiology of Clostridium difficile infectionsThe challenges posed by reemerging Clostridium difficile infection.Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trialRole of leptin-mediated colonic inflammation in defense against Clostridium difficile colitisImmune responses to Clostridium difficile infectionVancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcomeNitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.Use of International Classification of Diseases, Ninth Revision, Clinical Modification codes and medication use data to identify nosocomial Clostridium difficile infection.Prevalence of diverticulosis in recurrent Clostridium difficile infectionFaecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection.Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cellsEmergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.The potential value of Clostridium difficile vaccine: an economic computer simulation model.Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrheaClostridium difficile Infections: What Every Clinician Should KnowLack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in QuebecRisk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea.Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.Risk Factors for Delayed Recurrence of Clostridium difficile InfectionLong-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study
P2860
Q24234630-F69B869A-A476-40CB-839A-E083AF326C48Q24644191-4C3E3AF7-261C-422B-9C85-FEF819674BF5Q24676310-31F8EE92-A4D2-4231-A841-8BEE3EABD0E5Q26767079-F1E45313-F3E3-439A-B0F7-15FCCC705404Q26771995-0FB9977A-D255-4F4A-81C1-4D01511820AAQ26775010-140FC4DC-BEAB-4038-B7B9-5EA210AAA420Q27016320-FDCE438D-D814-4E31-AE7A-23BBBB6BB91FQ27021390-95E3D001-4EE8-42FE-B731-C49B1154CD70Q27308931-DE63B60B-34EB-48BF-810C-5DDABBD568BBQ28084026-D4FA7EE9-5E66-499F-9C50-02AE46EA3FA1Q28084700-F0DD6470-B97A-4675-95FA-F25C79E2D28FQ28084737-D828438A-9180-4D18-9AE3-83DFE842DFECQ28395557-C0E9C550-7849-4837-859F-C54E818E93F0Q28472543-C28C8872-FBF5-4609-A87C-8BA58A8B0BDAQ28750385-05F650B6-5B01-48DF-9102-0CBB9D51E437Q30229530-6FC43DF2-84B0-4F29-87F1-45B6FB794915Q30354419-B5F13ACC-E3C9-4B3F-9CE0-B23AFB9972EEQ30412148-CE3E4655-DFF9-4A02-9944-4B5BD22CB42BQ30416692-1751E916-EB33-4227-9210-C3D852FD8D9BQ30417830-3E4F5BC0-7403-48B1-9284-A5C5FD4C3F21Q30425705-30FF8C07-85C5-4B19-BC2D-D63D3D806AB7Q33276804-FC78B6A7-21FB-4917-BCC0-D4C13B490B37Q33285304-84FFBE89-EB47-4B38-B812-537C90BAA776Q33398747-8E7F3F14-6953-4EF6-B637-E8F1471FEB6AQ33508665-9DCF1CBE-781F-4B29-9A94-8C30D8AD6DC2Q33596510-AE6747B1-3259-42D3-BD6A-07710CD6ADB2Q33782277-D3586065-1927-4DBF-94E0-EA0B9970B6F3Q33810999-05D1FDE8-363A-4E19-9367-3F2E19B715F1Q33890323-20DD84B3-DE5B-466E-B6BC-B4AFA18F760CQ33990521-BF9182C4-792C-4869-BF74-DE04729C67DFQ34012314-1BE5544F-B6E5-4BD1-8938-648FDF5C3E18Q34018277-65F68473-001E-48AE-958F-19C31A59114DQ34028301-897B88B0-3D42-411B-8B19-E0AC676E2AC7Q34072892-169F793E-C46E-4C70-B5FC-54151AC4FED5Q34099215-8B3F3EEC-33F2-4C57-826C-96172FD30C9DQ34206660-9449F16B-6663-4309-8EC4-C90D5B54B499Q34306091-FCD62993-A95C-4F0F-93F6-00BBE3529B96Q34409185-7EA5C89F-B47C-4D11-94D7-80F9C861FCC7Q34429596-E516BBE5-EED8-4B1D-804F-6FB2E0B5CE60Q34429629-E5E6C9CB-2C84-44E4-94F5-1E93682DF883
P2860
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.
@en
Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.
@nl
type
label
Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.
@en
Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.
@nl
prefLabel
Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.
@en
Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.
@nl
P2093
P2860
P356
P1476
Increasing risk of relapse aft ...... ile colitis in Quebec, Canada.
@en
P2093
Claude Bourassa
Dominique Godin
Evelyne Raiche
Jacques Pepin
Joannie Ruel
Katalin Fulop
Marie-Eve Alary
P2860
P304
P356
10.1086/430315
P407
P577
2005-04-25T00:00:00Z